Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes
L Lamant, A Reyniès, MM Duplantier, DS Rickman… - Blood, 2007 - ashpublications.org
L Lamant, A Reyniès, MM Duplantier, DS Rickman, F Sabourdy, S Giuriato, L Brugières…
Blood, 2007•ashpublications.orgWith the use of microarray gene-expression profiling, we analyzed a homogeneous series of
32 patients with systemic anaplastic large-cell lymphoma (ALCL) and 5 ALCL cell lines.
Unsupervised analysis classified ALCL in 2 clusters, corresponding essentially to
morphologic subgroups (ie, common type vs small cell and “mixed” variants) and clinical
variables. Patients with a morphologic variant of ALCL had advanced-stage disease. This
group included a significant number of patients who experienced early relapse. Supervised …
32 patients with systemic anaplastic large-cell lymphoma (ALCL) and 5 ALCL cell lines.
Unsupervised analysis classified ALCL in 2 clusters, corresponding essentially to
morphologic subgroups (ie, common type vs small cell and “mixed” variants) and clinical
variables. Patients with a morphologic variant of ALCL had advanced-stage disease. This
group included a significant number of patients who experienced early relapse. Supervised …
Abstract
With the use of microarray gene-expression profiling, we analyzed a homogeneous series of 32 patients with systemic anaplastic large-cell lymphoma (ALCL) and 5 ALCL cell lines. Unsupervised analysis classified ALCL in 2 clusters, corresponding essentially to morphologic subgroups (ie, common type vs small cell and “mixed” variants) and clinical variables. Patients with a morphologic variant of ALCL had advanced-stage disease. This group included a significant number of patients who experienced early relapse. Supervised analysis showed that ALK+ALCL and ALK− ALCL have different gene-expression profiles, further confirming that they are different entities. Among the most significantly differentially expressed genes between ALK+ and ALK− samples, we found BCL6, PTPN12, CEBPB, and SERPINA1 genes to be overexpressed in ALK+ ALCL. This result was confirmed at the protein level for BCL-6, C/EBPβ and serpinA1 through tissue microarrays. The molecular signature of ALK− ALCL included overexpression of CCR7, CNTFR, IL22, and IL21 genes but did not provide any obvious clues to the molecular mechanism underlying this tumor subtype. Once confirmed on a larger number of patients, the results of the present study could be used for clinical and therapeutic management of patients at the time of diagnosis.
ashpublications.org